Pharma stocks underperformed during Trump’s first term. Will second term change the narrative?

Indian pharmaceutical stocks struggled during Donald Trump’s first term, with the Nifty Pharma index gaining just 20% compared to the Nifty 50’s stellar 80% returns. Headwinds like U.S. regulatory scrutiny, consolidation among buyers, and price pressures drove the underperformance.

With…